BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 18, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Dimebon latrepirdine: Development discontinued

Medivation and Pfizer discontinued development of Dimebon to treat HD after top-line data from the double-blind, international Phase III HORIZON trial in 403 patients showed that thrice-daily 20 mg oral Dimebon missed the co-primary endpoints of significantly improving cognition as measured by the MMSE and global function as measured by CIBIC-plus at 6 months vs. placebo (p=0.39 and p=0.84, respectively). Dimebon was generally...

Read the full 294 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >